Over the past 25 years, APP has been the object of intense interest because proteolytic cleavage in the juxtamembrane and transmembrane domains generates the beta-amyloid peptide that accumulates in patients with Alzheimer disease (AD) [3]. The gene discussed is APP; the disease is Alzheimer disease.